215 related articles for article (PubMed ID: 10598556)
1. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
Teicher BA; Alvarez E; Liu P; Lu K; Menon K; Dempsey J; Schultz RM
Semin Oncol; 1999 Apr; 26(2 Suppl 6):55-62. PubMed ID: 10598556
[TBL] [Abstract][Full Text] [Related]
2. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Teicher BA; Chen V; Shih C; Menon K; Forler PA; Phares VG; Amsrud T
Clin Cancer Res; 2000 Mar; 6(3):1016-23. PubMed ID: 10741729
[TBL] [Abstract][Full Text] [Related]
3. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
[TBL] [Abstract][Full Text] [Related]
4. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
5. Overview of phase II trials of MTA in solid tumors.
O'Dwyer PJ; Nelson K; Thornton DE
Semin Oncol; 1999 Apr; 26(2 Suppl 6):99-104. PubMed ID: 10598563
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors.
Thödtmann R; Depenbrock H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
Semin Oncol; 1999 Apr; 26(2 Suppl 6):89-93. PubMed ID: 10598561
[TBL] [Abstract][Full Text] [Related]
7. Overview of phase I trials of multitargeted antifolate (MTA, LY231514).
Rinaldi DA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560
[TBL] [Abstract][Full Text] [Related]
8. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
Scagliotti GV; Selvaggi G
Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
10. Overview of MTA in the treatment of non-small cell lung cancer.
Postmus PE; Green MR
Semin Oncol; 1999 Feb; 26(1 Suppl 4):31-6. PubMed ID: 10201519
[TBL] [Abstract][Full Text] [Related]
11. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
van der Wilt CL; Kuiper CM; Peters GJ
Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
[TBL] [Abstract][Full Text] [Related]
12. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
13. MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions.
Calvert H
Semin Oncol; 1999 Apr; 26(2 Suppl 6):105-8. PubMed ID: 10598564
[No Abstract] [Full Text] [Related]
14. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
15. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
[No Abstract] [Full Text] [Related]
17. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
[TBL] [Abstract][Full Text] [Related]
18. [Multi-targeted antifolate therapy roe non-small cell lung cancer and mesothelioma].
Le Chevallier T
Anticancer Drugs; 2001 Jul; 12 Suppl 3():S21-T5. PubMed ID: 11556250
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
20. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Schultz RM; Patel VF; Worzalla JF; Shih C
Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]